UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

1023 A Case of Stridor in the Sleep Clinic

Sleep (New York, N.Y.), 2023-05, Vol.46 (Supplement_1), p.A449-A450

2023

Volltextzugriff (PDF)

1024 A Challenging Inspire Case: All Roads Do Not Necessarily Lead to Rome

Sleep (New York, N.Y.), 2023-05, Vol.46 (Supplement_1), p.A450-A450

2023

Volltextzugriff (PDF)

1532 A phase 1/2 study of safety, tolerability, and pharmacokinetics of SNS-101, a pH-sensitive anti-VISTA mAb, as monotherapy and in combination with cemiplimab in patients with advanced solid tumors

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 2), p.A1755-A1755

2023

Volltextzugriff (PDF)

53-Year-Old Man With Fever and Hepatomegaly

Mayo Clinic proceedings, 2024-02, Vol.99 (2), p.312-317

2024

Volltextzugriff (PDF)

708 A phase 1/2 study of rinatabart sesutecan (PRO1184), a novel folate receptor alpha-directed antibody-drug conjugate, in patients with locally advanced and/or metastatic solid tumors

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A803-A803

2023

Volltextzugriff (PDF)

718 Phase 1/2 study of PRO1160, a CD70-directed antibody-drug conjugate, in patients with advanced solid tumors and hematologic malignancies

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A813-A813

2023

Volltextzugriff (PDF)

724 Subcutaneous nemvaleukin alfa in combination with pembrolizumab in patients with refractory solid tumors (ARTISTRY-2)

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A819-A819

2023

Volltextzugriff (PDF)

742 Phase 1/2 study of the bispecific 4–1BB and PD-L1 antibody INBRX-105 alone and in combination with pembrolizumab in select solid tumors

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A836-A837

2023

Volltextzugriff (PDF)

744 Assessment of safety and immunologic activity of nemvaleukin alfa in patients with advanced solid tumors treated with less frequent intravenous dosing (ARTISTRY-3)

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A839-A840

2023

Volltextzugriff (PDF)

Abstract B02: The Akt inhibitor MK-2206 in combination with rituximab and bendamustine demonstrates efficacy in relapsed/refractory chronic lymphocytic leukemia: Updated results from the NCCTG N1087 Alliance study

Molecular cancer therapeutics, 2015-07, Vol.14 (7_Supplement), p.B02-B02

2015

Volltextzugriff (PDF)

Abstract CT028: A first-in-human phase 1 study of LY3537982, a highly selective and potent KRAS G12C inhibitor in patients with KRAS G12C-mutant advanced solid tumors

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (8_Supplement), p.CT028-CT028

2023

Volltextzugriff (PDF)

Abstract CT077: An open-label phase 1 study to investigate SGN-CEACAM5C in adults with advanced solid tumors (SGNCEA5C-001, Trial in Progress)

Cancer research (Chicago, Ill.), 2024-04, Vol.84 (7_Supplement), p.CT077-CT077

2024

Volltextzugriff (PDF)

Abstract CT202: A first-in-human phase 1 study of LY3537982, a novel, highly selective and potent KRAS G12C inhibitor in patients with KRAS G12C mutant advanced solid tumors (trial in progress)

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.CT202-CT202

2022

Volltextzugriff (PDF)

Abstract CT244: Phase 1/2 study of PRO1184, a novel folate receptor alpha-directed antibody-drug conjugate, in patients with locally advanced and/or metastatic solid tumors

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (8_Supplement), p.CT244-CT244

2023

Volltextzugriff (PDF)

Abstract PO2-04-13: TWT-203: PHASE 1b/2 STUDY OF CFI-402257 AS MONOTHERAPY IN ADVANCED SOLID TUMORS AND IN COMBINATION WITH FULVESTRANT IN PATIENTS WITH ER+/HER2- ADVANCED BREAST CANCER AFTER PROGRESSION ON PRIOR CDK4/6 INHIBITORS AND ENDOCRINE THERAPY

Cancer research (Chicago, Ill.), 2024-05, Vol.84 (9_Supplement), p.PO2-04-13-PO2-04-13

2024

Volltextzugriff (PDF)

Akt inhibitor MK‐2206 in combination with bendamustine and rituximab in relapsed or refractory chronic lymphocytic leukemia: Results from the N1087 alliance study

American journal of hematology, 2017-08, Vol.92 (8), p.759-763

2017

Volltextzugriff (PDF)

Animal Metacognition: A Tale of Two Comparative Psychologies

Journal of comparative psychology (1983), 2014-05, Vol.128 (2), p.115-131

2014

Volltextzugriff (PDF)

ARRY-382 in Combination with Pembrolizumab in Patients with Advanced Solid Tumors: Results from a Phase 1b/2 Study

Clinical cancer research, 2022-06, Vol.28 (12), p.2517-2526

2022

Volltextzugriff (PDF)

Artificial Grammar Learning in Tamarins (Saguinus oedipus) in Varying Stimulus Contexts

Journal of comparative psychology (1983), 2017-05, Vol.131 (2), p.128-138

2017

Volltextzugriff (PDF)

An Atlas of Variant Effects to understand the genome at nucleotide resolution

Genome Biology, 2023-07, Vol.24 (1), p.147-147, Article 147

2023

Volltextzugriff (PDF)

Autoimmune cytopenias in patients with chronic lymphocytic leukaemia treated with ibrutinib in routine clinical practice at an academic medical centre

British journal of haematology, 2018-11, Vol.183 (3), p.421-427

2018

Volltextzugriff (PDF)

AXL Inhibition Improves the Antitumor Activity of Chimeric Antigen Receptor T Cells

Cancer immunology research, 2023-09, Vol.11 (9), p.1222-1236

2023

Volltextzugriff (PDF)

B-Cell Count and Survival: Differentiating Chronic Lymphocytic Leukemia (CLL) from and Monoclonal B-Cell Lymphocytosis (MBL) Based on Clinical Outcome

Blood, 2008-11, Vol.112 (11), p.2062-2062

2008

Volltextzugriff (PDF)

1 – 25 von 136

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(123)
Mit Volltextzugriff
(116)

Publikationsform

Sprache

Englisch
(135)
Französisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

1023 A Case of Stridor in the Sleep Clinic

1024 A Challenging Inspire Case: All Roads Do Not Necessarily Lead to Rome

1532 A phase 1/2 study of safety, tolerability, and pharmacokinetics of SNS-101, a pH-sensitive anti-VISTA mAb, as monotherapy and in combination with cemiplimab in patients with advanced solid tumors

53-Year-Old Man With Fever and Hepatomegaly

708 A phase 1/2 study of rinatabart sesutecan (PRO1184), a novel folate receptor alpha-directed antibody-drug conjugate, in patients with locally advanced and/or metastatic solid tumors

718 Phase 1/2 study of PRO1160, a CD70-directed antibody-drug conjugate, in patients with advanced solid tumors and hematologic malignancies

724 Subcutaneous nemvaleukin alfa in combination with pembrolizumab in patients with refractory solid tumors (ARTISTRY-2)

742 Phase 1/2 study of the bispecific 4–1BB and PD-L1 antibody INBRX-105 alone and in combination with pembrolizumab in select solid tumors

744 Assessment of safety and immunologic activity of nemvaleukin alfa in patients with advanced solid tumors treated with less frequent intravenous dosing (ARTISTRY-3)

Abstract B02: The Akt inhibitor MK-2206 in combination with rituximab and bendamustine demonstrates efficacy in relapsed/refractory chronic lymphocytic leukemia: Updated results from the NCCTG N1087 Alliance study

Abstract CT028: A first-in-human phase 1 study of LY3537982, a highly selective and potent KRAS G12C inhibitor in patients with KRAS G12C-mutant advanced solid tumors

Abstract CT077: An open-label phase 1 study to investigate SGN-CEACAM5C in adults with advanced solid tumors (SGNCEA5C-001, Trial in Progress)

Abstract CT202: A first-in-human phase 1 study of LY3537982, a novel, highly selective and potent KRAS G12C inhibitor in patients with KRAS G12C mutant advanced solid tumors (trial in progress)

Abstract CT244: Phase 1/2 study of PRO1184, a novel folate receptor alpha-directed antibody-drug conjugate, in patients with locally advanced and/or metastatic solid tumors

Abstract PO2-04-13: TWT-203: PHASE 1b/2 STUDY OF CFI-402257 AS MONOTHERAPY IN ADVANCED SOLID TUMORS AND IN COMBINATION WITH FULVESTRANT IN PATIENTS WITH ER+/HER2- ADVANCED BREAST CANCER AFTER PROGRESSION ON PRIOR CDK4/6 INHIBITORS AND ENDOCRINE THERAPY

Akt inhibitor MK‐2206 in combination with bendamustine and rituximab in relapsed or refractory chronic lymphocytic leukemia: Results from the N1087 alliance study

The AKT Inhibitor MK2206 In Combination With Rituximab and Bendamustine Is Tolerable and Active In Relapsed Or Refractory Chronic Lymphocytic Leukemia: Results From a Phase 1 Study (NCCTG N1087 Alliance)

Animal Metacognition: A Tale of Two Comparative Psychologies

ARRY-382 in Combination with Pembrolizumab in Patients with Advanced Solid Tumors: Results from a Phase 1b/2 Study

Artificial Grammar Learning in Tamarins (Saguinus oedipus) in Varying Stimulus Contexts

An Atlas of Variant Effects to understand the genome at nucleotide resolution

Autoimmune cytopenias in patients with chronic lymphocytic leukaemia treated with ibrutinib in routine clinical practice at an academic medical centre

AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells

AXL Inhibition Improves the Antitumor Activity of Chimeric Antigen Receptor T Cells

B-Cell Count and Survival: Differentiating Chronic Lymphocytic Leukemia (CLL) from and Monoclonal B-Cell Lymphocytosis (MBL) Based on Clinical Outcome

Suchergebnisse filtern